SCHEDULE: Vanguard Group Reports 0% Stake in Integra LifeSciences

The Vanguard Group filed an amended Schedule 13G, indicating a 0% beneficial ownership in Integra LifeSciences Holdings Corp following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 10 to its Schedule 13G for Integra LifeSciences Holdings Corp.
• The filing reports 0% beneficial ownership of Integra LifeSciences Holdings Corp common stock by The Vanguard Group.
• This change is due to an internal realignment at The Vanguard Group, Inc. on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions now report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It primarily reports a change in The Vanguard Group's internal reporting structure, not a direct positive or negative development for Integra LifeSciences itself.

Positives

• The filing clarifies a change in reporting structure, indicating a compliance-driven update rather than a strategic divestment by the broader Vanguard ecosystem.

Negatives

• The Vanguard Group, as the named reporting entity, no longer directly holds beneficial ownership in Integra LifeSciences, which might be perceived as a reduction in direct institutional interest from this specific entity.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Integra LifeSciences Holdings Corp's future performance or The Vanguard Group's future investment intentions beyond the reporting structure change.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.
• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing primarily reflects an internal organizational change within The Vanguard Group's reporting structure rather than a strategic investment decision regarding Integra LifeSciences. Such realignments are not uncommon for large asset managers and typically aim to optimize internal operations or regulatory compliance, without necessarily indicating a change in the overall investment thesis for the underlying company by Vanguard's broader fund complex.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for changes in beneficial ownership.
• The disaggregation of reporting by large investment advisers like Vanguard is a known practice, often done to comply with specific SEC guidance (e.g., Release No. 34-39538).
• It does not provide financial results for Integra LifeSciences to compare against industry benchmarks.

Stakeholder Impact

• Shareholders of Integra LifeSciences: May observe a change in the reported beneficial ownership by 'The Vanguard Group' specifically, but the broader Vanguard fund complex may still hold shares through other reporting entities.
• The Vanguard Group: The internal realignment impacts how its various entities report beneficial ownership, streamlining compliance.

Next Steps

• Future Schedule 13G filings for Integra LifeSciences Holdings Corp may come from Vanguard's disaggregated subsidiaries or business divisions.

Key Dates

Keywords

Vanguard Group, Integra LifeSciences Holdings Corp, Schedule 13G, Beneficial Ownership, Institutional Ownership, SEC Filing, Common Stock, Investment Adviser, Realignment